Executive and administrative shifts around CDC recommendations have generated confusion that clinicians report is being ...

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy ...

A narrative review finds insomnia is a consistent, dose-dependent cardiovascular risk factor, but trials have not shown that ...

Tara Graff highlighted the significance of 2025 as a landmark year for RRFL treatment, with the June 2025 approval of ...

Tara Graff discussed her experience with epcoritamab-based combinations in follicular lymphoma, noting that her practice's ...

In 'Empowering Community Oncology: Infrastructure Investments for Bringing Novel RRFL Therapies to Patients,' Tara Graff, DO, ...

Zanubrutinib may provide longer progression-free survival (PFS) than fludarabine, cyclophosphamide, and rituximab (FCR) in ...

“PsA rarely presents de novo; it usually evolves after a 3- to 10-year subclinical interval following cutaneous [psoriasis],” ...

Nearly 1 in 3 women aged 21 to 29 years had never been screened for cervical cancer by 2023, up from roughly 1 in 8 in 2005, according to a new research letter published in JAMA N ...

For Xavier Leleu, MD, PhD, there is opportunity to ensure that therapeutic advances are accompanied by advances in how those therapies are delivered. The treatment landscape for multiple myeloma (MM) ...

“ACO-SWITCH is a prospective study in adults with ATTR-CM,” wrote the researchers. “The study will determine the effects of ...

In "Unmet Needs and Long-Term Antiviral Safety in Hepatitis B Care," the panel explores where guideline adherence breaks down and what long-term antiviral safety data actually show.